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Abstract
Diabetes during pregnancy can adversely affect the health of women and infants. In this report, we 
provide an overview of the state of the science, and highlight Centers for Disease Control and 
Prevention (CDC) activities related to (1) surveillance of preexisting and gestational diabetes 
mellitus (GDM); (2) preconception care for women with preexisting diabetes; (3) postpartum 
diabetes screening among women with GDM-affected pregnancies; and (4) preventing the 
progression to Type 2 diabetes among women with GDM-affected pregnancies through lifestyle 
intervention programs. Improving preconception care, increasing postpartum diabetes screening 
rates, and promoting lifestyle interventions in the postpartum period all provide opportunities to 
improve the health of women and their infants.
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Introduction
In the United States, the prevalence of diabetes has increased by over 35% from 1988 
through 20121; in 2015, an estimated 12 million women ages 18 years or older had 
diagnosed diabetes and ~3 million had undiagnosed diabetes.2 Diabetes during pregnancy 
can adversely affect the health of women and their infants. Women with Type 1 or Type 2 
diabetes diagnosed before entering pregnancy, referred to in this article as preexisting 
diabetes, are at risk for elevated glucose levels and/or insulin resistance around the time of 
conception; this early exposure increases infants’ risk of congenital anomalies, stillbirth, and 
premature birth.3 Gestational diabetes mellitus (GDM) is diabetes that is first diagnosed 
during pregnancy,4 and could be a detection of undiagnosed preexisting diabetes or onset of 
diabetes at 24–28 weeks gestation, the latter typically reverting back to normal after 
delivery.5,6 For both women with preexisting diabetes or GDM, elevated glucose levels 
throughout pregnancy increases their risk of having a cesarean delivery, and increases 
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infants’ risk of being born too large (or macrosomic), hypoglycemic, and developing obesity 
or diabetes in the future.7–9 Women with GDM are also more likely to have recurrent GDM 
in subsequent pregnancies10,11 and to develop Type 2 diabetes later in life.12
In this report, we provide an overview of the state of the science, and describe select Centers 
for Disease Control and Prevention (CDC) activities related to (1) surveillance of preexisting 
diabetes and GDM; (2) preconception care for women with preexisting diabetes; (3) 
postpartum diabetes screening among women with GDM-affected pregnancies; and (4) 
preventing the progression to Type 2 diabetes among women with GDM-affected 
pregnancies through lifestyle intervention programs. We conclude by highlighting 
opportunities to improve each of these areas for promoting optimal maternal and infant 
health.
Surveillance of preexisting and gestational diabetes
Preexisting diabetes—Preexisting diabetes has been identified as a priority 
preconception health indicator by the National Preconception Health and Healthcare 
Initiative’s Surveillance and Research group.13,14 Few studies have specifically focused on 
the surveillance of Type 1 and Type 2 diabetes among reproductive aged women. 
Surveillance reports using Behavioral Risk Factor Surveillance System (BRFSS) data from 
50 states and the District of Columbia found the overall prevalence of self-reported Type 1 
and Type 2 diabetes among women ages 18–44 years was 3.0% in 200915 and 3.1% in 
2014–2015,14 with non-Hispanic black and older women having higher prevalence of 
diabetes compared to other race/ethnicity or age groups, respectively.15 Similarly, 2007–
2010 data from the National Health and Nutrition Examination Survey (NHANES) indicate 
that 3.2% of women ages 20–44 years had diabetes based on self-report or a fasting blood 
test.16 For surveillance purposes, BRFSS and NHANES are limited in that neither can 
discern Type 1 from Type 2 diabetes, and both provide self-reported diabetes status, which 
may be subject to respondent biases; however, both data sources provide national estimates 
of preexisting diabetes among reproductive age women, and BRFSS can also provide state-
specific estimates.
In the United States preexisting diabetes is estimated to affect 0.75%–2.1% of births,15,17 
with Type 2 diabetes more prevalent than Type 1.17–19 Furthermore, the prevalence of 
preexisting diabetes during pregnancy has increased. For example, one study using hospital 
discharge data from 19 states found preexisting diabetes increased from an age-adjusted 
prevalence of 0.65% in 2000 to 0.89% in 2010—a relative increase of 37%.20 Prevalence of 
preexisting diabetes in pregnancy varies by maternal age and race/ethnicity; specifically, 
older women17,21 and non-Hispanic black or Hispanic18,20 women are more likely to have 
pregnancies affected by this condition. Hospital discharge databases, which are often used 
for surveillance purposes, have been found to provide more sensitive estimates of preexisting 
diabetes than the birth certificate22; however, hospital discharge data often lack demographic 
information, such as complete data on race/ethnicity, education level, information on 
prenatal care, and previous birth outcomes, which are useful for understanding health 
disparities and guiding interventions. Although the 2003 revised birth certificate 
differentiates preexisting diabetes from GDM, national surveillance of preexisting diabetes 
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is limited because not all states adopted the revised birth certificate until 2016. Adoption by 
all states will enable national estimates of preexisting diabetes and GDM; unfortunately, 
these data will not enable discerning Type 1 from Type 2 diabetes. Studies have found that 
linking hospital discharge and birth certificate data provides a wider range of data and a 
more accurate source for identifying maternal diagnoses than a single source alone.22,23
Undiagnosed diabetes is a challenge to surveillance. In 2015, an estimated 4.0% of men and 
women ages 18–44 years in the United States had diabetes, of which approximately one-
third were undiagnosed.2 With continued increases in obesity and cardiovascular disease, 
there may be concurrent increases in undiagnosed diabetes. To our knowledge, NHANES is 
the only data system able to measure undiagnosed diabetes because it collects blood 
specimens on a subsample of participants in addition to self-reported diabetes. However, due 
to sample size limitations, undiagnosed diabetes estimates in pregnant women may not be 
reliable. Moreover, multiple years are needed to have a sufficient sample size to estimate 
undiagnosed diabetes among women of reproductive age.
Gestational diabetes—GDM is defined as diabetes with onset or first recognition during 
pregnancy.4 In the United States, 5.7%–8.7% of pregnancies are complicated by GDM24,25 
that represents 85%–90% of all pregnancy-related diabetes (Type 1, Type 2, and gestational).
21
 Among delivery hospitalizations, the prevalence of GDM increased more quickly than 
preexisting diabetes from 2000 to 2010; GDM prevalence increased 56% while preexisting 
diabetes increased 37%.26 Several studies have found that racial/ethnic minority women, 
especially Asian and Hispanic women, have a higher prevalence of GDM than non-Hispanic 
white women.24,26–28 Further, women who experienced GDM are 50%–80% more likely to 
develop GDM in a subsequent pregnancy,10 and even without GDM recurrence in the 
subsequent pregnancy, offspring from subsequent pregnancies are more likely to experience 
adverse health outcomes compared to offspring of mothers who never had GDM.29 A major 
challenge to surveillance of GDM is that screening practices and diagnostic thresholds for 
identifying women with GDM may vary by institution, which makes it difficult to determine 
whether changes in prevalence estimates reflect variation in clinical practice or true changes 
in the proportion of women with GDM. Revised birth certificate and hospital discharge data 
may be used for GDM surveillance; however, similar to preexisting diabetes, these data 
sources are limited by data quality concerns and lack of select demographic indicators, 
respectively.22
Preconception care
Preconception care is the provision of healthcare and medical interventions that that 
optimize women’s health and the health of an infant, should a pregnancy occur.30 For 
women with preexisting diabetes, preconception care provides an opportunity to review 
diabetes management to ensure appropriate glucose levels, adjust medications if needed, and 
evaluate and treat any medical complications. Women with preexisting diabetes intending to 
become pregnant may benefit from working with a dietitian to develop healthy practices 
such as logging meals and developing individualized meal plans.30 Consultation with a 
doctor and dietitian before pregnancy is important as diabetes management (e.g., 
medications) during pregnancy may differ from diabetes management before pregnancy.
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A Pregnancy Risk Assessment Monitoring System (PRAMS) study examining 10 states in 
2009–2010 found that 53% of women with preexisting diabetes, 32% with GDM, and 31% 
with no diabetes received preconception care before their pregnancy; preconception care was 
defined, as before pregnancy, talking with a doctor, nurse, or other healthcare worker to 
prepare for a healthy pregnancy and baby.31 A recent modeling study of 69,357 births to 
women with preexisting diabetes estimated that preconception care (which was defined as 
some combination of glycemic control, glucose monitoring, counseling, screening and 
treatment of diabetic complications, or contraception until glycemic control is achieved) 
could prevent 8397 preterm deliveries, 3725 birth defects, and 1897 perinatal deaths 
annually.32 Further, provision of the previously mentioned types of preconception care to an 
estimated 18,723 women with undiagnosed diabetes might avert an additional 2267 preterm 
deliveries, 1006 birth defects, and 505 perinatal deaths annually. For women of reproductive 
age, clinical assessment of associated risk factors and provision of recommended screening 
can identify undiagnosed diabetes. Reproductive age women can work with clinicians to 
achieve a healthy weight, engage in at least 150 minutes per week of moderate-intensity 
aerobic activity, and address other health behaviors that may put them at risk for developing 
or worsening diabetes.33
For reproductive aged women with diabetes, consulting with a healthcare provider is an 
opportunity to appropriately plan for pregnancy, as poor glucose control at conception and 
possibly early pregnancy increases the risk of congenital anomalies and stillbirth.3 For 
women with diabetes who want to delay or avoid pregnancy, the 2016 U.S. Medical 
Eligibility Criteria for Contraceptive Use provides recommendations for using specific 
contraceptive methods by women and men who have certain characteristics or medical 
conditions, including diabetes.34
Improve postpartum diabetes screening
Because 3%–14% of women who had a pregnancy affected by GDM will be diagnosed with 
overt Type 2 diabetes when tested 6 weeks postpartum and an additional 17%–25% will be 
diagnosed with impaired glucose tolerance,35–37 screening immediately postpartum and then 
periodic monitoring is important for early detection of Type 2 diabetes. The American 
College of Obstetricians and Gynecologists (ACOG) recommends screening women at 4–12 
weeks postpartum.7 If results are normal at 4–12 weeks, women are recommended to be 
tested every 1–3 years as part of lifelong monitoring. For women with impaired glucose 
tolerance, but not overt diabetes, yearly testing is recommended by the American Diabetes 
Association to monitor for the development of Type 2 diabetes.38 Women diagnosed with 
Type 2 diabetes at the postpartum screen are recommended to be referred for timely and 
appropriate follow-up care.
Nationally representative surveillance data on postpartum diabetes screening are not 
currently available. Estimates of postpartum diabetes screening range from 3.4% to 51.7% 
depending on the method of data collection and population studied.39–42 For example, a 
2011 study using Medicaid claims data from South Carolina found only 3.4% of women 
with GDM-affected pregnancies received diabetes screening 5–13 weeks postpartum39; in 
contrast, a study using 2000–2012 claims data from a nationwide commercial insurance 
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database found approximately one-quarter of women over the study period were screened in 
the year postpartum.42 In 2009–2010, roughly half of women with GDM-affected 
pregnancies from three states and one jurisdiction participating in PRAMS reported 
receiving diabetes screening postpartum.41 While postpartum diabetes screening on PRAMS 
is assessed via self-report and has not been validated, PRAMS provides state-representative 
estimates, and beginning in 2016, all 47 states participating in PRAMS will include 
questions on postpartum diabetes screening.
Overall, postpartum diabetes screening appears to be less than optimal, suggesting missed 
opportunities to diagnose, monitor, and provide appropriate medical care or interventions to 
treat Type 2 diabetes or that may prevent women from progressing to Type 2 diabetes.40 
Barriers to postpartum diabetes screening may be related to clinicians not providing 
appropriate referrals for the diabetes screening test; lack of health insurance and high out of 
pocket costs; or women not understanding the reason for postpartum testing, not having the 
time, or not wanting to get tested in the postpartum period after being tested for GDM 
during pregnancy.43,44 As women with a history of GDM transition from pregnancy to 
postpartum, establishing communication between obstetrical and primary care providers is 
key to improving postpartum diabetes screening and monitoring.45 A multilevel approach 
may need to be considered, which could include a reminder system incorporated into 
electronic medical records and an effective hand-off system of patient’s medical records 
involving a variety of healthcare settings, specialties, and levels of practitioners.43,45,46
Identifying alternative approaches to postpartum diabetes screening may improve screening 
rates. For example, the CDC Division of Reproductive Health funded researchers to 
investigate delivery hospitalizations as an opportunity for conducting postpartum diabetes 
screening. One study comparing diabetes screening at 6 weeks postpartum, the researchers 
found diabetes screening at delivery had a sensitivity of 100% and specificity of 94%,47 thus 
screening during delivery hospitalization may be a viable alternative to screening later in the 
postpartum period. Innovative methods are needed to address barriers to postpartum 
screening and improve related surveillance of postpartum diabetes screening.
Lifestyle interventions to prevent type 2 diabetes
Women who experience GDM are up to 70% more likely to develop Type 2 diabetes within 
10 years after a GDM-affected pregnancy.12 For women with a GDM history, the postpartum 
period is an opportunity to mitigate the risk of developing Type 2 diabetes by engaging in 
healthy dietary and physical activity behaviors and returning to prepregnancy weight.48,49 
Women are encouraged to return to their prepregnancy weight because weight gained during 
pregnancy and maintained postpartum can increase body mass index and GDM risk in 
subsequent pregnancies. Although national estimates of postpartum weight retention are 
unavailable, studies across the United States report a range of 13%–20% of pregnant women 
retained at least 5 kg by 1 year postpartum.50 In a large cohort study of 12,583 women in the 
United Kingdom, 73% retained at least some of the weight gained during pregnancy at 6 
months postpartum.51 Furthermore, postpartum weight retention among women with GDM-
affected pregnancies may increase the risk of mothers developing Type 2 diabetes later in 
life. For example, one study followed women for 18 years and found for each 5 kg increase 
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in weight after diagnosis of GDM, the risk of developing Type 2 diabetes increased by 27%.
52
Lifestyle interventions that include diet and physical activity have been shown to reduce 
postpartum weight retention and reduce the risk of developing Type 2 diabetes.53 However, 
new mothers face unique barriers to engaging in lifestyle interventions, including time 
constraints, childcare responsibilities, and fatigue.54 To address these challenges, CDC 
funded researchers to develop a lifestyle intervention program for women with a recently 
GDM-affected pregnancy called Balance After Baby. This year-long pilot program provided 
women in the intervention group with a lifestyle coach, a pedometer, and access to online 
modules modeled after the Diabetes Prevention Program.55 In addition, the program 
included dietary suggestions to assist in transitioning from a GDM diet and an exercise 
component with activities involving the baby. Women in the control group received usual 
care from their healthcare providers.56 The pilot results showed that women in the 
intervention group lost a mean of 2.8 kg from 6 weeks to 12 months postpartum compared to 
the control group who gained a mean of 0.5 kg. The study is currently being scaled up to 
include more sites, English and Spanish language versions, and 2 years of follow-up to 
examine maintenance of weight loss after the intervention is complete. Balance After Baby 
was specifically designed for women in the first year postpartum, with a goal to reduce 
postpartum weight retention and ultimately prevent women from developing future 
prediabetes or Type 2 diabetes. However, women with a history of GDM, or women who 
develop prediabetes, are also eligible to participate in the National Diabetes Prevention 
Program (National DPP), which includes a yearlong lifestyle change program designed to 
prevent or delay type 2 diabetes. The National DPP is an evidence-based intervention 
coordinated by CDC, and includes thousands of CDC-recognized organizations delivering 
the program to hundreds of thousands of people in-person, virtually, or through a 
combination of virtual and in-person modalities to accommodate different learning styles 
and preferences.
Summary and Conclusion
Glucose intolerance before, during, and after pregnancy has important health implications 
for both mothers and their babies. In this overview, we highlight work related to 
surveillance, preconception care, and postpartum care and opportunity for improvements. To 
strengthen surveillance, efforts may need to focus on improving current data sources by 
linking existing data sources (such as birth certificate and hospital discharge data), 
improving quality of data to increase sensitivity of preexisting diabetes and GDM estimates, 
and accurately capture postpartum screening rates. By improving surveillance systems, 
public health researchers, practitioners, and clinicians may better understand the prevalence 
and related public health burden of diabetic conditions during pregnancy; in turn, this will 
allow improved development and targeting of interventions, programs, and policy.
In addition to surveillance, opportunities exist to improve preconception and postpartum 
healthcare for women with preexisting or gestational diabetes. Preconception care for 
women with preexisting diabetes to obtain proper glucose control might prevent potential 
adverse pregnancy and birth outcomes. In the postpartum period, improvements to 
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healthcare are needed to ensure women with a GDM-affected pregnancy are screened for 
diabetes. These improvements may require a multilevel approach that addresses barriers at 
the patient, clinician and healthcare-system level. Finally, given the high progression rate of 
GDM to Type 2 diabetes, improved availability of lifestyle interventions are needed, 
especially those that address the unique barriers postpartum women face.
We have a unique opportunity to prevent future development of Type 2 diabetes among 
women whose pregnancies are affected by GDM. By identifying ways to improve 
preconception care for women with preexisting diabetes, ensure appropriate postpartum 
diabetes screening and postpartum care among women with a GDM-affected pregnancy, and 
provide opportunities for changes in lifestyle, we might significantly improve the health of 
women and prevent future adverse pregnancy outcomes.
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